GlobeNewswire

TriLumina Launches the World’s First Surface-Mount Flip-Chip Back-Emitting VCSEL Array Without the Need for a Submount

Share

Game-changing “LED Killer” Device Enables Lowest Cost, Smallest, High Performance for Mobile 3D Sensing Applications and Innovative NIR Illumination Options

ALBUQUERQUE, N.M., June 20, 2019 (GLOBE NEWSWIRE) -- TriLumina, the leading developer of flip-chip VCSEL(vertical-cavity surface-emitting laser) technology for 3D sensing, announces the launch of the world’s first surface-mount flip-chip back-emitting VCSEL array without the need for a submount or bond wires, which allows for lower costs and higher performance than existing designs using near-infrared light-emitting laser diodes or LEDs for 3D sensing.

“We are pleased to launch this revolutionary device,” said Luke Smithwick, chief marketing officer for TriLumina. “For the first time, engineers can create extremely small, low-cost, high-performance products utilizing a NIR surface mount back-emitting VCSEL array, without the need for a large and costly submount.”

Conventional VCSEL arrays are mounted on a submount and use bond wires for electrical connections.  TriLumina’s unique patented Flip-chip, back-emitting VCSEL technology has been flip-chip packaged and used in automotive long-range LiDAR prototypes, for low power mobile and in-cabin 3D sensing applications. The new 4 W Chip on Board (CoB) SMT (surface mount technology) VCSEL device is a compact, surface-mountable design, consisting of a single VCSEL array die, that is mountable on a printed circuit board (PCB) without the need for a submount carrier for the VCSEL die. This tiny, very low-cost illumination technology is an excellent solution for numerous 3D sensing applications, as well as providing innovative NIR illumination options for replacing existing LEDs in solutions such as NIR camera systems, mobile cameras, in-cabin occupant monitoring and AR/VR systems. TriLumina’s integrated back-side etched micro-lenses enable integrated optics, which further reduces part height as compared to conventional VCSELs with separate optical lenses and can result in lower battery drain with multi-zone operation. It has the smallest footprint with the lowest cost implementation in its class, making it ideal for use in mobile devices.

“TriLumina has led VCSEL illumination for 3D sensing with our innovative flip-chip back-emitting multi-chip illumination modules for long range LiDAR applications,” said Brian Wong, president and chief executive officer of TriLumina. “Now, we’ve innovated once again, by eliminating the need for a package for low-power mobile and automotive in-cabin applications.”

This new architecture from TriLumina has excellent thermal properties with a very compact form factor. The VCSEL device has integrated solder balls and mounts directly to a PCB using standard surface mount technology (SMT), with built-in hermeticity. The CoB SMT VCSEL array eliminates the need for wire bonds or other expensive packaging technology found on standard top-emitting VCSELs. Although the device is designed for efficient operation in indirect Time of Flight (ToF) applications, the lack of wire bonds also has inherently low parasitic inductance, making this emitter compatible with ultra-high-resolution, fast rise-time, short pulse-width direct ToF applications.

Contact TriLumina for a data sheet and additional technical and pricing information.

ABOUT TRILUMINA CORPORATION
TriLumina Corporation develops innovative laser illumination solutions for automotive, industrial, and consumer 3D sensing applications. TriLumina near-infrared VCSEL technology is used in applications from long range LiDAR to low cost, small form factor ToF systems. Please visit http://www.trilumina.com for more information.

Media Contact
Jason Farrell | jfarrell@elevationb2b.com | (480) 539-2706

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8fb9e17-43bf-459e-8f21-f6922920e2df

https://www.globenewswire.com/NewsRoom/AttachmentNg/e4c45798-819e-42fe-b83d-e55ef9af61dc

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Active Biotechs valberedning utsedd19.11.2019 16:00:00 CETPressemelding

PRESSMEDDELANDE Enligt beslut från årsstämman den 23 maj 2019, ska valberedningen för Active Biotech bestå av representanter för de, i slutet av september månad 2019, röstmässigt tre största ägarna, samt styrelsens ordförande. Valberedningen ska till årsstämman 2020 föreslå bland annat styrelseledamöter och styrelseordförande samt arvoden till styrelseledamöter och revisorer. Följande personer har utsetts till representanter för de röstmässigt största aktieägarna i valberedningen: Mats Arnhög, MGA Holding Angela Langemar Olsson, Nordstjernan Per Colleen, 4:e AP Fonden Valberedningen kommer under styrelseordförande Michael Shalmis ledning utarbeta förslag att föreläggas för beslut på årsstämman den 19 maj 2020. Lund den 19 november 2019 Active Biotech AB (publ) Helén Tuvesson Verkställande direktör För ytterligare information, vänligen kontakta: Hans Kolam, CFO Tfn 046 19 20 44 Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) är ett bioteknikföretag fokuserat på utveckling av läkemedel

Active Biotech's election committee appointed19.11.2019 16:00:00 CETPress release

PRESS RELEASE In accordance with a decision made by the Annual General Meeting held on May 23, 2019, the Election Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2019, and the Chairman of the Board. For the 2020 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders by votes and, accordingly, are members of the Election Committee: Mats Arnhög, MGA Holding Angela Langemar Olsson, Nordstjernan Per Colleen, 4:e AP Fonden Under the leadership of the Chairman of the Board, Michael Shalmi, the Election Committee shall prepare proposals to be presented to and decided upon at the Annual General Meeting on May 19, 2020. Lund, November 19, 2019 Active Biotech AB (publ) Helén Tuvesson President and CEO For further information, please contact: Hans Kolam, CFO T

Svensk Hypotekspension Fond 3 AB (publ) – Uppdateringar till det skriftliga förfarandet, initierat den 5 november 201919.11.2019 15:45:00 CETPressemelding

Pressmeddelande den 19 november 2019 Svensk Hypotekspension Fond 3 AB (publ) – Uppdateringar till det skriftliga förfarandet, initierat den 5 november 2019 Intertrust (Sweden) AB, i egenskap av agent (”Agenten”), har på begäran av Svensk Hypotekspension Fond 3 AB (publ) (”Emittenten”) i dag skickat ett meddelande (”Meddelandet”) relaterat till det skriftliga förfarandet som initierades den 5 november 2019 (det ”Skriftliga Förfarandet”) för de SEK 2 000 000 000 bolånesäkrade fastränteobligationerna med ISIN SE0007691621 utgivna av Emittenten den 9 februari 2016 (”Obligationerna”), så som beskrivet i Emittentens pressmeddelande från den 5 november 2019. Meddelandet skickades till de direktregistrerade ägare och registrerade förvaltare av Obligationerna som angavs i den skuldbok som förs av Euroclear Sweden den 4 och den 11 november 2019. Meddelandet Syftet med det Skriftliga Förfarandet är att godkänna eller att avvisa en begäran från Emittenten om en föreslagen ändring av bestämmelserna

Svensk Hypotekspension Fond 3 AB (publ) – Updates relating to the written procedure initiated on 5 November 201919.11.2019 15:45:00 CETPress release

Press release 19 November 2019 Svensk Hypotekspension Fond 3 AB (publ) – Updates relating to the written procedure initiated on 5 November 2019 Intertrust (Sweden) AB, acting as agent (the ”Agent”), has today on the request of Svensk Hypotekspension Fond 3 AB (publ) (the ”Issuer”) sent a notice (the “Notice”) relating to the written procedure initiated on 5 November 2019 (the “Written Procedure”) for the SEK 2,000,000,000 Mortgage Backed Fixed Rate Notes with ISIN SE0007691621 issued by the Issuer on 9 February 2016 (the “Notes”), as further described in the Issuer’s press release on 5 November 2019. The Notice was sent to the direct registered owners and registered authorised nominees (förvaltare) of the Notes recorded as of 4 and 11 November 2019, respectively, in the debt ledger (skuldbok) produced by Euroclear Sweden. The Notice The purpose of the Written Procedure is to approve or reject a request from the Issuer regarding a proposed amendment to the redemption provisions in the t

Iconovo har erhållit godkänt patent i Japan19.11.2019 15:09:00 CETPressemelding

Den japanska patentmyndigheten har godkänt ett patent avseende Iconovos inhalator, ICOres. Iconovo har sedan tidigare flera godkända svenska patent samt ett europeiskt patent på ICOres, men detta är det första i Japan. ICOres är den inhalator som används i Iconovos två stora kundprojekt där bland annat generisk SymbicortÒ ingår. ”Ett godkänt patent är nyckeln till den stora och viktiga japanska marknaden. Det är en fördel för våra befintliga kunder som ska kunna lansera ICOres-produkter i Japan”, säger Orest Lastow, VD. För ytterligare information, vänligen kontakta Orest Lastow, VD, orest.lastow@iconovo.se, mobil: 076-5422220. Om ICOres ICOres är en nyskapande reservoarbaserad torrpulverinhalator som är utvecklad av Iconovo. Den kan anpassas för att ha flera olika yttre former och färger för att passa olika kunders speciella krav. ICOres har två separata reservoarer vilket gör den speciellt väl lämpad till kombinationsprodukter. ICOres har även flera unika egenskaper och funktioner fö

Iconovo has been granted ICOres patent in Japan19.11.2019 15:09:00 CETPress release

The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several granted ICOres patents in Sweden and in Europe, but this is the first in Japan. ICOres is the dry powder inhaler used in Iconovo’s two major customer projects including generic SymbicortÒ. ”A granted patent is the key to this huge and important market. This will be an advantage to our customers when launching ICOres products in Japan”, says Dr Orest Lastow, CEO. For further information please contact: Orest Lastow, VD, orest.lastow@iconovo.se, telephone: 076-5422220. About ICOres ICOres is a novel reservoir-based dry powder inhaler developed by Iconovo. It can be designed in many different shapes and colors and customized to meet a customer’s unique requirements. ICOres has two separate reservoirs and is particularly suitable for combination products. ICOres has several unique compliance enhancing features as an accurate dose counter showing each remaining dose, a vi